UBCS039

Last updated

UBCS039
UBCS039 structure.png
Clinical data
Drug class Sirtuin-6 (SIRT6) activator
Identifiers
  • 4-pyridin-3-yl-4,5-dihydropyrrolo[1,2-a]quinoxaline
CAS Number
PubChem CID
Chemical and physical data
Formula C16H13N3
Molar mass 247.301 g·mol−1
3D model (JSmol)
  • C1=CC=C2C(=C1)NC(C3=CC=CN32)C4=CN=CC=C4
  • InChI=1S/C16H13N3/c1-2-7-14-13(6-1)18-16(12-5-3-9-17-11-12)15-8-4-10-19(14)15/h1-11,16,18H
  • Key:BSOBGTYXYGHUTD-UHFFFAOYSA-N

UBCS039 is a drug which acts as a sirtuin-6 (SIRT6) activator. It was the first synthetic SIRT6 activator to be developed, and while it has comparatively lower potency compared to some newer agents, it is still widely used in research. It has antiinflammatory effects and is protective against kidney toxicity, as well as showing beneficial actions against lung and liver damage, cadmium toxicity, and arterial thrombosis. [1] [2] [3] [4] [5] [6] [7] [8]

References

  1. ↑ Iachettini S, Trisciuoglio D, Rotili D, Lucidi A, Salvati E, Zizza P, et al. (September 2018). "Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells". Cell Death & Disease. 9 (10) 996. doi:10.1038/s41419-018-1065-0. PMC   6155207 . PMID   30250025.
  2. ↑ Wang QL, Yang L, Liu ZL, Peng Y, Gao M, Deng LT, et al. (February 2022). "Sirtuin 6 regulates macrophage polarization to alleviate sepsis-induced acute respiratory distress syndrome via dual mechanisms dependent on and independent of autophagy". Cytotherapy. 24 (2): 149–160. doi:10.1016/j.jcyt.2021.09.001. PMID   34920961.
  3. ↑ Jiao F, Zhang Z, Hu H, Zhang Y, Xiong Y (2022). "SIRT6 Activator UBCS039 Inhibits Thioacetamide-Induced Hepatic Injury In Vitro and In Vivo". Frontiers in Pharmacology. 13 837544. doi: 10.3389/fphar.2022.837544 . PMC   9065480 . PMID   35517808.
  4. ↑ Liu Y, Wang T, Zhou Q, Xin G, Niu H, Li F, et al. (2023). "Endogenous SIRT6 in platelets negatively regulates platelet activation and thrombosis". Frontiers in Pharmacology. 14 1268708. doi: 10.3389/fphar.2023.1268708 . PMC   10766690 . PMID   38186648.
  5. ↑ Miao H, Wang YN, Su W, Zou L, Zhuang SG, Yu XY, et al. (January 2024). "Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1/β-catenin pathway". Acta Pharmacologica Sinica. 45 (1): 137–149. doi:10.1038/s41401-023-01148-w. PMC   10770168 . PMID   37640899.
  6. ↑ Zhang J, Xiong YW, Zhu HL, Tan LL, Zhou H, Zheng XM, et al. (September 2024). "Adolescent co-exposure to environmental cadmium and high-fat diet induces cognitive decline via Larp7 m6A-mediated SIRT6 inhibition". Journal of Hazardous Materials. 476 135159. Bibcode:2024JHzM..47635159Z. doi:10.1016/j.jhazmat.2024.135159. PMID   39002485.
  7. ↑ Wang D, Zhou Y, Yang N, Liu J, Lu L, Gao Z (July 2025). "SIRT6 mitigates acute kidney injury by enhancing lipid metabolism and reducing tubular epithelial cell apoptosis via suppression of the ACMSD signaling pathway". Cellular Signalling. 131 111757. doi:10.1016/j.cellsig.2025.111757. PMID   40120964.
  8. ↑ Sinha R, Singh P, Zeng H, Kumar A, Antony VB (September 2025). "Cadmium exposure triggers vimentin phosphorylation via SIRT6-regulated AKT/PI3K signaling pathway in COPD". European Journal of Cell Biology. 104 (3) 151503. doi:10.1016/j.ejcb.2025.151503. PMID   40609497.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.